Inhaled Flecainide Formulation for Rapid Cardiac Cardioversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac arrhythmias, such as atrial fibrillation and paroxysmal supraventricular tachycardia, face challenges including high side-effect profiles, the need for extensive monitoring, and the requirement for high doses of medications that can lead to adverse cardiac events and prolonged hospital stays, with existing oral and intravenous medications being inadequate in efficacy and safety.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of flecainide acetate or flecainide hydrochloride in a liquid solution with a concentration above 60 mg/mL, potentially combined with cyclodextrin and an acid, administered via inhalation using a nebulizer to achieve rapid and safe cardioversion with minimal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of oral or intravenous medications are used to achieve cardioversion, then the therapeutic effect is improved, but the risk of adverse cardiac events and side effects increases
Solution Approach 1:
The patent uses cyclodextrin as an intermediary substance to form an inclusion complex with flecainide. This complex allows the drug to be delivered at high concentrations directly to the heart tissue without causing systemic toxicity. The cyclodextrin acts as a carrier that protects the drug during transit and releases it at the target site, thereby achieving therapeutic efficacy while minimizing adverse cardiac events.
Solution Approach 2:
The invention achieves local high concentration of flecainide at the cardiac tissue site while maintaining low systemic concentration. The intracoronary administration route delivers the drug directly to the coronary circulation, and the cyclodextrin inclusion complex ensures localized release at the heart muscle, providing high therapeutic effect where needed while avoiding systemic side effects.
2Speed
If high concentrations of flecainide are administered to achieve rapid cardioversion, then the onset speed is improved, but the risk of QT prolongation and torsade de pointes increases
Solution Approach 1:
Cyclodextrin serves as a mediator that enables high-dose flecainide administration without proportional increase in toxicity. The inclusion complex formation allows the drug to reach therapeutic concentrations rapidly while the cyclodextrin structure prevents excessive drug accumulation in cardiac ion channels, thereby avoiding QT prolongation and torsade de pointes even at high doses.
Solution Approach 2:
The patent changes the physical-chemical parameters of drug delivery by forming an inclusion complex with cyclodextrin. This modification alters the pharmacokinetic profile, allowing rapid onset of action while controlling the maximum plasma concentration and tissue exposure, thereby preventing QT interval prolongation despite high therapeutic doses.
3Speed
If intravenous administration is used to achieve rapid drug delivery, then the delivery speed is improved, but the need for hospital monitoring and extensive medical resources increases
Solution Approach 1:
The cyclodextrin inclusion complex acts as a safe carrier that enables rapid intracoronary delivery without the safety concerns that would require extensive monitoring. The complex reduces systemic toxicity and cardiac side effects, allowing the procedure to be performed with minimal monitoring requirements, thereby reducing device complexity and hospital resource needs while maintaining fast delivery speed.
4Ease of operation
If oral medications are used for treatment, then the ease of administration is improved, but the time to onset of action increases
Solution Approach 1:
The patent extracts the drug from the oral administration route and delivers it directly to the coronary circulation via intracoronary injection. This eliminates the need for gastrointestinal absorption and first-pass metabolism, reducing the time to onset of action from over an hour to minutes, while the cyclodextrin complex ensures safety at these higher, faster-acting doses.
Data Source
AI summary
Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.